Tanya Simuni, MD
Tanya Simuni, MD
Dr Simuni heads the Northwestern University Feinberg school of Medicine movement disorders center that is recognized by the Parkinson’s Foundation, Huntington’s disease and Wilson’s Foundations as Centers of Excellence. She is the world recognized expert in Parkinson’s disease modification studies. She is the principal investigator on a multicenter phase III clinical trial evaluating isradipine as a potential disease-modifying agent in early PD supported by the National Institute of Health and Phase II study of Nilotinib supported by MJFF as well as recently NINDS funded study of telemedicine and smart phone technology for long term assessment of participants in PD clinical trials. She serves on a number of Steering Committees for PD national clinical trials, several committees of the Parkinson Study Group and the Parkinson Foundation. She is the Site PI and serves on the Steering Committee for the MJFF PPMI study. Dr. Simuni is the site PI for the Network for Excellence in Neuroscience Clinical Trials (NEXT) Northwestern Clinical Site (U10). She has more than hundred publications in peer-reviewed scientific journals and book chapters and she has lectured nationally and internationally on PD and other movement disorders.
Dr Simuni is an active member of the Movement Disorders Society, the International Association of Parkinsonism and Related Disorders, the American Academy of Neurology, American Neurological Association, as well as the Parkinson’s Study Group, and REM Behavior Disorders Study Group.
Dr Simuni heads the Northwestern University Feinberg school of Medicine movement disorders center that is recognized by the Parkinson’s Foundation, Huntington’s disease and Wilson’s Foundations as Centers of Excellence. She is the world recognized expert in Parkinson’s disease modification studies. She is the principal investigator on a multicenter phase III clinical trial evaluating isradipine as a potential disease-modifying agent in early PD supported by the National Institute of Health and Phase II study of Nilotinib supported by MJFF as well as recently NINDS funded study of telemedicine and smart phone technology for long term assessment of participants in PD clinical trials. She serves on a number of Steering Committees for PD national clinical trials, several committees of the Parkinson Study Group and the Parkinson Foundation. She is the Site PI and serves on the Steering Committee for the MJFF PPMI study. Dr. Simuni is the site PI for the Network for Excellence in Neuroscience Clinical Trials (NEXT) Northwestern Clinical Site (U10). She has more than hundred publications in peer-reviewed scientific journals and book chapters and she has lectured nationally and internationally on PD and other movement disorders.
Dr Simuni is an active member of the Movement Disorders Society, the International Association of Parkinsonism and Related Disorders, the American Academy of Neurology, American Neurological Association, as well as the Parkinson’s Study Group, and REM Behavior Disorders Study Group.
